With Only 15% of Diagnosed HCV Patients Receiving Treatment, the Non-Profit I-MAK Hopes to Shift the National Conversation on Drug Pricing
FDA publishes shame list of firms fighting generic competitors
FDA shames companies accused of blocking generic drug development
Trump is right: Abusive patents are the culprit behind high drug prices, but his plan doesn’t solve anything
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents
Tahir Amin: Increasing Access to Affordable HIV Drugs Through Patent Opposition
A Supreme Court victory for lowering drug prices
Tahir Amin: Transparency in Drug Pricing
Tahir Amin: Pay-for-Delay Settlements and Patient Access
Tahir Amin: The Role of Advocacy Groups in the Patent System